中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
7期
475-479
,共5页
周远达%夏雨人(综述)%李强(审校)
週遠達%夏雨人(綜述)%李彊(審校)
주원체%하우인(종술)%리강(심교)
神经内分泌肿瘤%诊断%手术%靶向治疗
神經內分泌腫瘤%診斷%手術%靶嚮治療
신경내분비종류%진단%수술%파향치료
neuroendocrine tumors%diagnosis%surgery%targeted therapy
近年许多分子标志物与影像学诊断技术应用于胰腺神经内分泌肿瘤(PNET)的诊断,大幅提高了PNET的诊断准确性。在PNET的治疗方面,手术切除仍是唯一具有治愈可能的治疗方式,根据肿瘤的类型、部位、大小情况可以选择不同的手术方式。而传统的化疗由于不良反应大等原因,临床应用有限。但是随着对PNET发病机制的了解,生长抑素类似物、血管生成抑制剂、mTOR抑制剂等靶向药物已经应用于临床,为PNETs患者带来了希望。
近年許多分子標誌物與影像學診斷技術應用于胰腺神經內分泌腫瘤(PNET)的診斷,大幅提高瞭PNET的診斷準確性。在PNET的治療方麵,手術切除仍是唯一具有治愈可能的治療方式,根據腫瘤的類型、部位、大小情況可以選擇不同的手術方式。而傳統的化療由于不良反應大等原因,臨床應用有限。但是隨著對PNET髮病機製的瞭解,生長抑素類似物、血管生成抑製劑、mTOR抑製劑等靶嚮藥物已經應用于臨床,為PNETs患者帶來瞭希望。
근년허다분자표지물여영상학진단기술응용우이선신경내분비종류(PNET)적진단,대폭제고료PNET적진단준학성。재PNET적치료방면,수술절제잉시유일구유치유가능적치료방식,근거종류적류형、부위、대소정황가이선택불동적수술방식。이전통적화료유우불량반응대등원인,림상응용유한。단시수착대PNET발병궤제적료해,생장억소유사물、혈관생성억제제、mTOR억제제등파향약물이경응용우림상,위PNETs환자대래료희망。
Pancreatic neuroendocrine tumors (PNETs) have an annual incidence of approximately 1 per 100,000 individuals and most often occur in adults aged 40 years to 60 years. PNETs, also called islet cell tumors, originate from the Langerhans cells in the pan-creatic islet. Based on the presence or absence of specific hormone-related symptoms, PNETs are classified as either functional or non-functional. Depending on their clinicopathological characteristics, these tumors can also be classified as G1, G2, or G3 in the World Health Organization classification and grading system. The American Joint Committee on Cancer and European Neuroendocrine Tumor Society has also introduced the TNM staging classification for PNETs. New technologies, including molecular markers and med-ical imaging, have been used to diagnose PNET and have significantly improved the diagnostic accuracy. As for the treatment of PNET, surgery may be the only option. Different modes of surgery can be used depending on the tumor type, location, and size. Clinical appli-cation of traditional chemotherapeutic agents is limited because of their toxicity. However, with the increased understanding of PNET pathogenesis, therapeutic agents such as somatostatin analogs, angiogenesis inhibitors, and mTOR inhibitors have already been used in clinical practice and have brought hope to patients.